-
ESTABLISHING A LEADER IN CELL-BASED IMMUNOTHERAPIES BUILT ON DECADES OF EXPERTISE IN THE FIELD OF ALLOGENEIC DENDRITIC CELL BIOLOGY
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
About us
Developing innovative cancer immunotherapies
Immunicum is advancing novel cell-based approaches to treat blood-borne and solid tumors.
Learn more
Press Releases
Immunicum and the University Medical Center Groningen Receive a Grant from Health~Holland to Broaden Cancer Relapse Vaccine Development for Ovarian Cancer
08 Sep 2021Immunicum Announces Participation in Multiple Upcoming Industry and Investor Events in September and October
27 Aug 2021Immunicum AB (publ) Interim Report April - June 2021
26 Aug 2021
Video
Upcoming Events
-
SACHS Biotech in Europe Forum
7 -8 Oct 2021 -
ESGO Hybrid Meeting
23 -25 Oct 2021 -
Annual Neoantigen Based Therapies Summit
26 -28 Oct 2021 -
SITC Annual Meeting
10 -14 Nov 2021 -
Cellular Immunotherapies for Solid Tumors Summit
16 -18 Nov 2021
News
-
European Hematology Association (EHA) 2021 Virtual Meeting – Posters
11 Jun 2021 -
Immunicum Corporate Presentation at Redeye Growth Day 2021
8 Jun 2021 -
Immunicum Investor Event on April 22, 2021 at 1:00 pm CET
19 Apr 2021 -
Virtual Investor Event Materials
8 Dec 2020 -
Transaction Webcast Presentation
19 Nov 2020
